

CURRICULUM VITAE

DATE:

May 13, 2025

NAME:

Steven R. Bergmann, M.D., Ph.D.

PRESENT TITLE:

Senior Medical Director
Cardiovascular Services
eviCore Healthcare

OFFICE ADDRESS:

730 Cool Springs Blvd.
Suite 800
Franklin, TN 37067

TELEPHONE NUMBER:

800.918.8924 Ext 28393

EMAIL ADDRESS:

steven.bergmann@evicore.com

CITIZENSHIP:

United States

EDUCATION:

- | | | |
|----|--|---------|
| A. | George Washington University
Washington, DC
B.A. (Zoology) | 05/1972 |
| B. | Hahnemann Medical College
Philadelphia, PA
Ph.D. (Physiology & Biophysics) | 06/1978 |
| C. | Washington University School of Medicine
St. Louis, MO
M.D. | 05/1985 |

POSTGRADUATE TRAINING:

- | | |
|----|--|
| A. | Intern
Barnes-Jewish Hospital
St. Louis, MO
Internal Medicine
07/1986–06/1988 (done half-time) |
| B. | Resident
Barnes-Jewish Hospital
St. Louis, MO
Internal Medicine
07/1994–06/1996 |
| C. | Fellow in Cardiovascular Disease
Washington University Program
St. Louis, MO
07/1988–06/1990 |
| D. | Specialized Training in Nuclear Cardiology |

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Mallinckrodt Institute of Radiology
St. Louis, MO
01/1994-06/1994

- E. NIH Post-doctoral Fellow
Cardiovascular Division
Department of Internal Medicine
Washington University School of Medicine
St. Louis, MO
09/1977-06/1980

MILITARY: N/A

ACADEMIC APPOINTMENTS:

Senior Vice President for Medical Affairs Penn Medicine/Princeton Health Plainsboro, NJ	01/01/2018-12/31/2020
Chair, Department of Medicine Penn Medicine/Princeton Health Plainsboro, NJ	07/01/2016-12/31/2020
Site Director Physician Assistant Program Princeton Medical Center, Internal Medicine rotation Rutgers School of Health Professions Piscataway, NJ	04/2017-12/31/2020
Clinical Professor of Medicine Rutgers/Robert Wood Johnson Medical School New Brunswick, NJ	11/2016-12/31/2020
Associate Dean for Academic Affiliate-Medical School Relationships Rutgers/Robert Wood Johnson Medical School New Brunswick, NJ	10/2016-12/31/2020
Professor of Medicine (Primary) Professor of Diagnostic Imaging and Therapeutics University of Connecticut School of Medicine Farmington, CT	10/2014-06/2016
Senior Associate Dean, Faculty Affairs University of Connecticut School of Medicine Farmington, CT	04/2014-07/2015
Visiting Professor of Medicine (Primary) Visiting Professor of Diagnostic Imaging and Therapeutics University of Connecticut School of Medicine Farmington, CT	04/2014-10/2014
Professor of Medicine (Primary) Professor of Radiology Icahn School of Medicine at Mount Sinai New York, NY	01/2014-06/2014

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Professor of Radiology Department of Radiology Albert Einstein College of Medicine of Yeshiva University New York, NY	01/2012 – 12/2014
Professor of Nuclear Medicine Department of Nuclear Medicine Albert Einstein College of Medicine of Yeshiva University New York, NY	09/2003 – 12/2011
Professor of Medicine Department of Medicine Albert Einstein College of Medicine of Yeshiva University New York, NY	09/2003 – 12/2014
Adjunct Professor of Medicine Department of Medicine College of Physicians and Surgeons of Columbia University New York, NY	09/2003 – 06/2008
Margaret Milliken Hatch Professor of Medicine, with Tenure Division of Cardiology, Department of Medicine College of Physicians & Surgeons of Columbia University New York, NY	10/2002 – 08/2003
Professor of Radiology Department of Radiology College of Physicians & Surgeons of Columbia University New York, NY	09/1996 – 08/2003
Professor of Medicine, with Tenure Division of Cardiology, Department of Medicine College of Physicians & Surgeons of Columbia University New York, NY	09/1996 – 10/2002
Adjunct Professor of Medicine Cardiovascular Division, Department of Medicine Washington University School of Medicine, St. Louis, MO	09/1996 – 06/1997
Professor of Radiology Mallinckrodt Institute of Radiology Washington University School of Medicine, St. Louis, MO	07/1995 – 08/1996
Professor of Medicine, with Tenure Cardiovascular Division, Department of Internal Medicine Washington University School of Medicine, St. Louis, MO	07/1995 – 08/1996
Associate Professor of Radiology Mallinckrodt Institute of Radiology Washington University School of Medicine, St. Louis, MO	07/1994 – 08/1995
Associate Professor of Medicine, Cardiovascular Division, Department of Internal Medicine Washington University School of Medicine, St. Louis, MO	07/1989 – 06/1995
Assistant Professor of Medicine Cardiovascular Division, Department of Internal Medicine Washington University School of Medicine, St. Louis, MO	07/1985 – 06/1989

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Assistant Professor of Medical Physiology in Medicine
Cardiovascular Division, Department of Internal Medicine
Washington University School of Medicine, St. Louis, MO 07/1980 – 06/1985
(Part-time 1982 – 1985)

Research Instructor in Medicine,
Cardiovascular Division, Department of Internal Medicine
Washington University School of Medicine, St. Louis, MO 09/1979 – 06/1980

Hospital Appointments:

Honorary Medical Staff
Penn Medicine – Princeton Health
Plainsboro, NJ 01/01/2021-date

Medical Director, Princeton Healthcare Associated Physicians, PC
Penn Medicine – Princeton Health
Plainsboro, NJ 08/2018-12/31/2020

Senior Vice President for Medical Affairs
Penn Medicine Princeton Medical Center
Plainsboro, NJ 01/2018-12/31/2020

Chair, Department of Medicine
Attending Physician
Medicine
Penn Medicine/Princeton Medical Center
(Formerly Princeton HealthCare)
Plainsboro, NJ 07/2016-12/31/2020

Attending Physician (Medicine and Cardiology)
John Dempsey Hospital
University of Connecticut School of Medicine
Farmington, CT 04/2014-06/2016

Vice Chair for Academic Affairs, Department of Medicine
Beth Israel Medical Center, New York, NY 05/2009 – 04/2014

Medical Director and Chair, Heart Institute
Continuum Health Partners, New York, NY 09/2003 – 09/2013

Chief, Thomas Killip Division of Cardiology
Beth Israel Medical Center, New York, NY 09/2003 – 04/2014

Attending Physician (Medicine and Cardiology)
Beth Israel Medical Center, New York, NY 09/2003 – 04/2014

Director, Nuclear Cardiology
Columbia-Presbyterian Medical Center, New York, NY 09/1996 – 08/2003

Attending Physician (Medicine and Cardiology)
New York Presbyterian Hospital-Columbia Campus, New York, NY 09/1996 – 08/2003

Medical Director, Nuclear Cardiology
Cardiovascular Division, Barnes-Jewish Hospital, St. Louis, MO 07/1994 – 08/1996

Attending Physician (Medicine and Cardiology)
Barnes Hospital, St. Louis, MO 07/1994 - 08/1996

OTHER EMPLOYMENT:

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Associate Medical Director
Cardiology
eviCore Healthcare
Bluffton, SC

01/04/2021-05/20/2022

Medical Director and Subject Matter Expert
Cardiovascular Services
eviCore Healthcare
Bluffton, SC

05/20/2021-date

PRIVATE PRACTICE: N/A

LICENSURE:

Physician

Active:

Arizona – 70917

Delaware – C1-0026275

Florida – ME 139469

Kentucky – C1788

Louisiana - 337880

Maryland – D98101

Minnesota – 74791

Mississippi - 32012

Montana - MED-PHYS-COM-LIC-128289

Nevada- 24000

New Hampshire – 24509

New Jersey – 25MA09875000

North Dakota - 20077

Oklahoma - 42020

Tennessee – 66010

Texas –U5571

Washington State IMLC.MD.61467365

Wisconsin – 3237-320

Inactive/Expired:

Connecticut – 527723 (inactive)

New York – 204096 (inactive)

Missouri – 105214(expired)

Medical Expert – Florida – MEEW2480

DRUG LICENSURE:

NJ CDS D10806400

DEA: BB7504017

XX7504017

CERTIFICATION:

Board Certified - American Board of Internal Medicine (Expires 12/31/2023)

Board Certified – Certification Board of Nuclear Cardiology (Expires 03/01/2024)

MEMBERSHIPS, OFFICES and COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

Fellow, American College of Cardiology

Fellow, American College of Physicians

Senior Member, American Society of Clinical Investigation

Member, American Society of Nuclear Cardiology

Greater New York Working Group

Co-director 1997 - 2003

Program Committee Advance Track, 2001, 2002

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Member, Quality Assurance Committee, 2001-2005
Member, Continuing Medical Education Committee, 2000 - 2003
Senior Member, Association of University Cardiologists
Fellow, New York Academy of Medicine (inactive)
Member, Society of Nuclear Medicine (inactive)
Course Organization
Annual Scientific Sessions
2000 – 2002

HONORS AND AWARDS:

John R. Smith Memorial Fund Prize for Meritorious Work in Cardiovascular Disease,
Washington University School of Medicine, 1985
Paul Schweitzer Award for Excellence in Teaching,
Thomas Killip Division of Cardiology, Beth Israel Medicinal Center, 2005
America's Top Physicians, 2004-2005
America's Top Cardiologists, Consumer's Research Council of America, 2006, 2008- 2010, 2015-2017
Best Doctors in America, 2001-2014
Best Physicians, US News & World Report, 2012-2015
Castle Connolly Top Doctors: 2006-2015
Healthgrades Honor Roll
Top Doctors, New York Magazine, 2014
Top Doctors, 2020
Acute Coronary Syndrome Team, 2002 American Association of Critical Care Nurses Multidisciplinary Award
VHA Health Foundation 2002 Award-Winner for Clinical Effectiveness: Single Hospital. New York Presbyterian
Hospital, New York, NY, "Acute Coronary Syndromes / Chest Pain Initiative"
State of Connecticut Certificate of Appreciation – awarded for work in the Department of Public Health, Public
Health Practitioner Investigations Section, December, 2015
Who's Who in America, 2001-2003, 2007, 2009, 2013
Who's Who in American Education – 2006-2009
Who's Who in Frontier Science and Technology, 1984
Who's Who in Medicine and Healthcare, 2002, 2006-2007
Who's Who in Science and Engineering, 2003, 2006-2009
Who's Who in the World, 2006
New York Super Doctors 2008 - 2014
The Global Directory of Who's Who 2008
Honorary Membership - Societatea Medicilor Internisti Din Republica Moldova (Internal Medicine Society of the
Republic of Moldova), May, 2011

BOARDS OF DIRECTORS/TRUSTEE POSITIONS:

Princeton Medicine Princeton Health Religious Ministries
Board of Directors, 2019-12/31/2020

American Heart Association, Missouri Affiliate
Board of Directors, 1993 -1996
Member, Executive Committee, 1993 – 1994

American Society of Nuclear Cardiology
Board of Directors, 1999 - 2003

Society of Nuclear Medicine
Cardiovascular Council Board of Directors
2000 – 2002
Board of Trustees - Cardiovascular Council, 1992 – 1994

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Department of Energy, Office of Energy Research, Office of Biological and Environmental Research, Grant Reviewer, 2014

Certification Board of Nuclear Cardiology
Chair, Board Examination Writing Committee
2001 – 2003

National Heart, Lung, and Blood Institute - Special Emphasis Review
SCCOR in Pediatric Heart Development & Disease
Member, NIH Study Section, 2003

National Institute of Diabetes and Digestive and Kidney Disease
Digestive Diseases and Nutrition C Subcommittee
Study Section Ad Hoc Reviewer, 2002

National Heart, Lung, and Blood Institute, National Institutes of Health, Cardiovascular and Renal Study Section
Ad Hoc Member, 1993

American Heart Association, Missouri Affiliate
Research Committee
Member, 1992 - 1996
Chairman, 1993 – 1994

Peer-Review Committee
Member, 1987 - 1993
Chairman, 1992 – 1993

Veterans Administration Merit Program
Ad Hoc Reviewer, 1988

SERVICE ON MAJOR COMMITTEES:

A. *International - N/A*

B. *National*

C. *Medical School/University*

Animal Studies Committee
Washington University School of Medicine, St. Louis, MO
Member 1990 -1994
Vice-Chairman 1992 - 1993

Animal Studies Executive Committee
Washington University School of Medicine, St. Louis, MO
Vice-Chairman and Member 1992 - 1993

Animal Care Program Review Committee of the Executive Faculty,
Washington University School of Medicine, St. Louis, MO
Member 1994 - 1996

Academic Freedom and Tenure Hearing Committee,
Washington University School of Medicine, St. Louis, MO
Alternate Member 1991 – 1994

Joint Radiation Safety Committee
College of Physicians & Surgeons of Columbia University
Columbia-Presbyterian Medical Center, New York, NY
Member 1996 – 2003
Executive Committee 1996 - 2003
Deputy Chair 2000 – 2007

Radioactive Drug Research Committee

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

College of Physicians & Surgeons of Columbia University Columbia-Presbyterian Medical Center, New York, NY Member	1999 – 2003
Dean's Select Committee Albert Einstein College of Medicine, New York, NY	2007 - 2013
<i>D. Hospital</i>	
Member: By-Laws Committee Combined Committee Continuing Education Committee	2016-12/31/2020
Credentials Committee Department Chairs Committee Information Systems Advisory Committee Institutional Review Board Medical Staff Nominating Committee New Technology Committee Pharmacy and Therapeutics Committee Performance Improvement Committee Penn Medicine Princeton Health, Plainsboro, NJ	
Chair, Code and Rapid Response Committee Beth Israel Medical Center, New York, NY	2005-2014
Chair, Cardiovascular Subcommittee Pharmacy & Therapeutics Committee Continuum Health Partners, New York, NY	2005 - 2013
Chair, Radiation Safety Committee Beth Israel Medical Center, New York, NY	2007 - 2014
Chair, Search Committee for Chief of Pulmonary, Critical Care and Sleep Medicine Beth Israel Medical Center, New York, NY	2008 and 2012
Co-Chair – Value Analysis – Cardiovascular Committee Continuum Health Partners, New York, NY	2011 – 2013
<i>E. Departmental</i>	
Chairman, Committee for Scientific Integrity Cardiovascular Division, Department of Internal Medicine Washington University School of Medicine, St. Louis, MO	1989 -1996
Executive Committee, Department of Medicine College of Physicians & Surgeons of Columbia University New York, NY	1996 – 2003
Executive Committee, Division of Cardiology College of Physicians & Surgeons of Columbia University New York, NY	1996 - 2003
Member, Promotions Committee, Department of Internal Medicine, Albert Einstein College of Medicine, New York, NY	2004 – 2013
Chair, Committee on Promotions, Dept. of Internal Medicine Beth Israel Medical Center, New York, NY,	2008 – 2014

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Scientific Advisory Board - Center for Cardiovascular Research,
Washington University School of Medicine, 1987 - 1996

F. Editorial Boards

Current:

Coronary Artery Disease
Journal of Nuclear Cardiology

Past:

Circulation
Journal of Nuclear Medicine

G. Ad Hoc Reviewer

American Journal of Physiology
Circulation
Circulation Research
Journal American College of Cardiology
Journal of Racial and Ethnic Health Disparities
New England Journal of Medicine
Teaching and Learning in Medicine

SERVICE ON GRADUATE SCHOOL COMMITTEES; N/A

SERVICE ON HOSPITAL COMMITTEES See above

SERVICE TO THE COMMUNITY

Member, Biomedical Research Alliance of New York (BRANY)
Institutional Review Board, 2004 – 12/31/2020

International Medical Missions
Moldova- 2011
El Salvador - 2011, 2013; 2016, 2018, 2019
Nicaragua - 2015

Medical Consultant – Department of Health
Office of Professional Medical Conduct
State of New York, 2002 – 2014

Medical Consultant – Department of Public Health
Practitioner Licensing and Investigations Section
State of Connecticut, 2014-2016

New York City Medical Response Corps
Member, 2011-2014

United States Coast Guard Auxiliary
Vice Flotilla Commander, 2016
Flotilla Staff Officer – Secretary/Records 2015-2016
Flotilla Staff Officer – Vessel Examination – 2014-2016
Flotilla Staff Officer – Human Resources – 2022-date
Instructor
Vessel Examiner
USCG Medical Service – 2024 - date

SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREEE

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Jou Wei Lin, D.Sc., College of Physicians and Surgeons of Columbia University
Kathleen Hickey, Ed.D., College of Physicians and Surgeons of Columbia University
Served on 6 dissertation committees.

SPONSORSHIP OF POSTDOCTORAL FELLOWS:

Faculty mentor to 16 post-doctoral fellows, 2 Masters students and 1 M.A.-M.D. student.

TEACHING RESPONSIBILITIES

- A. Lectures or Course Directorships – N/A
- B. Research Training – Prior – responsible for training Master's, pre-doctoral and post-doctoral students

Lectures in clinical assessment of chest pain, clinical pathways, research, myocardial perfusion, mechanical function, myocardial viability, and nuclear cardiology to Cardiovascular Division Fellows, Medicine House Staff, medical students and Radiology House Staff
~20 hours/year

Clinical and bedside teaching on telemetry unit and Cardiac Intensive Care Unit to Cardiovascular Division Fellows, Medicine House Staff and medical students 3 months/year, 15 hours/week

At Rutgers/Robert Wood Johnson, would be willing to teach Cardiology/Radiology/Nuclear Medicine to medical students, residents and fellows. Will be doing teaching rounds at University Medical Center of Princeton at Plainsboro with medical students and residents. Will mentor medical students and residents in clinical research projects.

CLINICAL RESPONSIBILITIES:

Outpatient consultative cardiology, nuclear cardiology, stress testing, CCU attending, telemetry attending, in patient cardiology consultation.

GRANT SUPPORT:

A. Principal Investigator

(Site Investigator)

Quantify Use of ANTicoagUlation to improve Management of AF (QUANTUM AF)

Janssen Pharmaceuticals, 3/28/18-7/1/2020

Total project costs direct costs: \$34,000

Annual project direct costs: \$17,000

Randomized controlled trial of a mobile app with patient financial incentives for tracking and improving adherence to medications and daily self-weighing to reduce heart failure readmissions

Wellth, 2/1/17-7/1/2020

Total direct costs: \$10,000

Noninvasive Imaging of Administered Progenitor Cells (DOE DE-FG02-03ER63600)

Department of Energy, 7/1/03 – 11/30/06

Total project direct costs: \$656,677

Annual project direct costs: \$186,518

Use of Echocardiographic Contrast Perfusion Imaging for Assessment of Efficacy of Progenitor Cell Therapy (Supplement DOE-DE FG02-03ER63600)

Department of Energy Grant, 9/1/2004 - 12/31/2004

Total project direct costs: \$ 77,181

Detection and Assessment Using Positron Emission Tomography of Defects in Myocardial Fatty Acid Utilization in Cardiomyopathy (DOE DE-FG02-97ER62433)

Department of Energy 6/1/01 - 11/30/04

Total project direct costs: \$1,080,000

Annual project direct costs: \$300,000

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Responsible Investigator, A State-of-the-Art PET scanner for Medical Research
(M. Laruelle, Principal Investigator) (1-S10-RR13961-01), 4/1/99 - 03/31/00
Total project direct costs: \$400,000

Protection of Myocardium by Modification of Metabolism (RO1 HL58408), 12/01/96 - 11/30/99
Total project direct costs: \$703,352
Annual project direct costs: \$165,493

Optimization of PET Estimates of Myocardial Perfusion (RO1 HL46895-06), 8/16/91 - 1/31/98
Total project direct costs: \$990,000
Annual project direct costs: \$170,238

Detection and Assessment Using Positron Emission Tomography of Genetically Determined Defects in
Myocardial Fatty Acid Utilization (DOE DE-FG02-93ER61659), 8/93 - 1/97
Total project direct costs: \$975,829
Annual project direct costs: \$388,000

Responsible Investigator, Principles in Cardiovascular Research Training Program 5-, Factors Modifying
Recovery of Myocardial Perfusion, Oxidative Metabolism, and Function after Coronary Recanalization
(B. E. Sobel, Principal Investigator) (T32-HL 07081, Project #13),
6/90 - 5/95
Total project direct costs: \$2,408,425
Annual project direct costs: \$ 489,176

Responsible Investigator, Specialized Center of Research in Coronary and Vascular Disease, Factors
Modifying Recovery of Myocardial Perfusion, Oxidative Metabolism, and Function after Coronary
Recanalization (B. E. Sobel, Principal Investigator) (HL17646, Project #5), 1/90 - 12/94
Total project direct costs: \$ 977,256
Annual direct costs: \$ 166,580

Responsible Investigator, Factors Modifying Recovery of Myocardial Perfusion, Oxidative Metabolism,
and Function after Coronary Recanalization (B. E. Sobel, Principal Investigator)(Specialized Center Of
Research #HL17646, Project 4), 1/90 - 12/94
Total project direct costs: \$ 977,256
Annual project direct costs: \$ 209,462

Responsible Investigator, Experimental PET Studies (L. J. Thomas, Principal Investigator) (Resource for
Biomedical Computing, 5 T41 RR01380-08, Project A-5), 12/88 - 11/92
Total project direct costs: \$2,734,530
Annual project direct costs: \$ 546,906

Responsible Investigator, Quantitative Assessment of Myocardial Perfusion and Its Response to
Thrombolysis with Tissue-type Plasminogen Activator by Positron Emission tomography (B. E. Sobel,
Principal Investigator) (Principles in Cardiovascular Research Training Program, 5-T32-HL 067081,
Project #5), 7/85 - 6/90
Total project direct costs: \$1,292,958
Annual project direct costs: \$ 252,444

Responsible Investigator, External Characterization of Myocardial Metabolism and Perfusion with
Positron-Emitting Radionuclides (B. E. Sobel, Principal Investigator) (Specialized Center of Research in
Ischemic Heart Disease, HL17646, Project #6), 1/85 - 12/89
Total project direct costs: \$ 690,855
Annual project direct costs: \$ 117,763

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Responsible Investigator, Characterization of Myocardial Metabolism in Diabetes (W. H. Daugherty, Principal Investigator) (Diabetes Research and Training Center, 5P60 AM 20579-05, Project #28), 9/81 - 9/83

Total direct costs: \$ 36,585

Annual direct costs: \$ 17,028

Optimization of PET Estimates of Myocardial Perfusion (RO1 HL46895), 8/91 - 7/97

Total project direct costs: \$479,392

Annual project direct costs: \$155,156

Responsible Investigator, Assessment of Myocardial Metabolism and Blood Flow During Ischemia and Reperfusion: Effects of Adjunctive Pharmacologic Therapy in Residual Stenosis (A. L. Schwartz, Principal Investigator) (Cardiovascular System: Function, Regulation, and Pharmacology, 5-T32-HL07275, Project #7), 9/92 - 6/98

Total project direct costs: \$1,517,000

Annual project direct costs: \$ 314,350

Principal Investigator Non-governmental Grants:

Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 1/14/2008 - 2010.

Total project direct costs: Estimated \$100,000/year

Responsible Investigator, Assessment of Myocardial Metabolism and Blood Flow During Ischemia and Reperfusion: Effects of Adjunctive Pharmacologic Therapy in Residual Stenosis (P. B. Corr, Principal Investigator) (Cardiovascular System: Function, Regulation, and Pharmacology, 5-T32-HL 07272, Project #7), 7/87 - 6/92

Total project direct costs: \$1,707,410

Annual project direct costs: \$ 341,482

Open-label, phase 2B study of the safety and efficacy of ¹²³I-BMIPP for identification of ischemic myocardium using SPECT in adults admitted to the emergency department for evaluation of symptoms consistent with ACS

Biostream 9/1/04 - 12/31/05

Total project direct costs: \$150,000

A Phase 2 Study of the Safety and Efficacy of β -Methyl-p-[¹²³I]-Iodophenyl-Pentadecanoic Acid (¹²³I-BMIPP) for the Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (SPECT) in Patients with an Ischemic Event

Biostream 7/1/02 - 6/30/03

Total project direct costs: \$158,000

Use of Copper-62-PTSM and Positron Emission Tomography for Quantitation of Myocardial Perfusion American Heart Association, 7/90 - 6/92

Total project direct costs: \$ 49,973

Annual project direct costs: \$ 24,981

Evaluation of Effects on Myocardial Perfusion Using Positron Emission Tomography (PET)

Eli Lilly and Company, 10/10/00 - 12/31/02

Total and Annual project direct costs: \$171,550

Relative and Absolute Myocardial Perfusion Changes as Measured by Positron Emission Tomography (PET) to Assess the Effects of ACAT Inhibition: A Double-Blind, Randomized, Multicenter Trial (RAMPART) Parke-Davis Pharmaceutical Research

1/1/99 - 12/31/99

Total project direct costs: \$250,000

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Advancement of the PET Program for the Diagnosis and Treatment of Heart Disease
Jacob and Hilda Blaustein Foundation, 7/01/98 - 6/30/01
Total project direct costs: \$300,000
Annual project direct costs: \$100,000

B. Co- Investigator

Collaborator, Body Composition: Methods, Models and Applications (S. Heymsfield, Principal Investigator) (2 P01 DK042618-11), 07/01/01 - 06/30/04
Total project direct costs: \$780,000
Annual project direct costs: \$156,000

Sponsor, Effects of mass regression on the physiological abnormalities associated with left ventricular hypertrophy (O. Akinboboye, Principal Investigator) (3-M01-RR00645-2753),
7/1/99 - 6/30/04
Total project direct costs: \$133,872 Annual project direct costs: \$ 39,314

Collaborator, Role of Aldose Reductase in Cardiac Ischemic Injury (R. Ramasamy, Principal Investigator) (RO1 HL61783), 12/1/98 - 11/30/03
Total project direct costs: \$557,141
Annual project direct costs: \$129,278 Collaborator, Console upgrade for a 4.23 T

Whole-body MR system (D. Shungu, Principal Investigator, S10 RR13881-01A1
4/1/00 - 3/31/01
Total project direct costs: \$400,000
Annual project direct costs: \$400,000

Co-Investigator, Improved Analysis and Display of Cardiac PET Images (T. R. Miller, Principal Investigator) (RO1 HL-42884), 4/90 - 3/93
Total project direct costs: \$ 350,129
Annual project direct costs: \$ 139,235

Co-Investigator, Biological Determinants of Acute Coronary Syndromes Delineated by Positron Emission Tomography (E. M. Geltman, Responsible Investigator, B. E. Sobel, Principal Investigator) (Specialized Center Of Research #HL17646, Project #12), 1/90 - 12/94
Total project direct costs: \$ 882,390
Annual project direct costs: \$ 144,859

Co-investigator, Biological Determinants of Acute Coronary Syndromes Delineated by Positron Emission Tomography (B. E. Sobel, Principal Investigator) (Specialized Center of Research in Coronary and Vascular Disease, HL17646, Project #14), 1/90 - 12/94
Total project direct costs: \$1,243,422
Annual project direct costs: \$ 176,478

Participating Investigator, Computer and Replacement Parts for Positron Emission Tomography (M. E. Raichle, Principal Investigator) (Shared Instrumentation Grant, RR04865-0),
12/88 - 12/89
Total and annual project direct costs: \$360,724

Participating Investigator, Cardiovascular Studies (M. M. Ter-Pogossian, Principal Investigator) (Cyclotron Produced Isotopes in Biology and Medicine, P01HL 13851, Project #3), 3/87 - 2/92
Total project direct costs: \$6,938,012
Annual project direct costs: \$1,189,983

Participating Investigator, Cardiovascular Studies (M. M. Ter-Pogossian, Principal Investigator) (Cyclotron Produced Isotopes in Biology and Medicine, P01 HL 14851, Project #3),
12/81 - 11/86
Total project direct costs: \$5,706,871

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Annual project direct costs: \$ 658,729

Collaborator, Whitaker Foundation Development Award, "Bridging Engineering, Medicine and Biology with an Emphasis on Biomedical Imaging" (V. Mow, Principal Investigator),
Years 2000 – 2005

Total project direct costs: \$10,000,000

Co-Investigator, PET Imaging of Cardiac Autonomic Nerves in Patients Who Have Diabetes Mellitus [J.T. Bigger, Principal Investigator] (Dana Foundation Award) 7/1/00 – 6/30/03

Total project costs: \$100,000

Annual project direct costs: \$50,000

Co-Investigator, Gated Blood Pool SPECT Analysis of Cardiac Function [K. Nichols, Principal Investigator] [Siemens Medical Systems, Inc.], 2/01/01 – 2/01/03

Total project direct costs: \$200,000

Annual project direct costs: \$150,000

Collaborator, Inhibition of Reperfusion Injury After Coronary Thrombolysis (P.R. Eisenberg, Principal Investigator) (Washington University/Monsanto Biomedical Program), 1/95 - 1/96

Total project direct costs: \$ 364,598

Annual direct costs: \$ 128,351

Principal Investigator, Characterization of Myocardial Metabolism in Perfusion with Positron Emitting Radionuclides (American Heart Association Summer Student Fellowship, American Heart Association, Missouri Affiliate), 7/93 - 8/94

Total project direct costs: \$ 2,000

Faculty Mentor, Effects of Modifying Fatty Acid Metabolism on Alcohol-Induced Myocardial Dysfunction (J-L. J. Vanoverschelde, recipient) (American Heart Association, Missouri Affiliate Postdoctoral Fellowship Award), 7/91 - 6/92

Total project direct costs: \$ 25,000

Faculty Mentor, Metabolic Cell with Stunned Myocardium (Marc Janier, recipient) (American Heart Association, Missouri Affiliate, Affiliate Postdoctoral Fellowship), 7/91 - 6/92

Total project direct costs: \$ 25,000

Participating Investigator, The Impact of Conjunctive Therapy on Coronary Thrombolysis (B.E. Sobel, Principal Investigator) (Monsanto/Washington University Development Program),
1/91 - 12/93

Total project direct costs: \$ 884,986

Annual project direct costs: \$ 265,000

Faculty Mentor, Evaluation of Perfusion Abnormalities in the Transplanted Heart (M. J. Senneff, recipient) (Mallinckrodt Fellowship/Society of Nuclear Medicine Award), 7/90 - 6/91

Total project direct costs: \$ 30,000

Faculty Mentor, Characterization of Myocardial Metabolism in Diabetes Mellitus Minority Faculty Fellowship Program (L. E. Fields, recipient) (Robert Wood Johnson Foundation, Grant R9067), 9/83 - 8/87

Total project direct costs: \$100,000

Annual project direct costs: \$ 25,000

Pending: None

PUBLICATIONS:

Peer Reviewed Articles

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

1. **Bergmann SR**, Tran, M, Robison KJ, Fanning C, Sedani S, Ready J, Conklin K, Lachica L, Paculdo D, Peabody JW. Standardizing Hospitalist Practice in Sepsis and COPD Care. *BMJ Quality and Safety*. 2019; 10:800-808.
2. Dilsizian V, Bacharach SL, Beanlands RS, **Bergmann SR**, Delbeke D, Dorbala S, Gropler RJ, Knuuti J, Schelbert HR, Travin MI. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. *J Nucl Cardiol*. 2016; 23:1187-1226. <https://www.ncbi.nlm.nih.gov/pubmed/27392702>
3. Zhu Z, Islam S, **Bergmann SR***. Effectiveness and outcomes of a nurse practitioner run chest pain evaluation unit. *J. Am. Assoc Nurse Practitioners. J Am Assoc Nurse Pract*. 2016; 28:591-595.
4. Ratcliffe JA, Wilson E, Islam S, Platsman Z, Leou K, Williams G, Lucido D, Moustakakis E, Rachko M, **Bergmann SR***. Mortality in the coronary care unit. *Coronary Artery Disease*. 2014; 25:60-65.
5. Kato S, Shimada YJ, Friedmann P, Kashan G, Husk G, **Bergmann SR***. Identification of residual risk factors for the development of venous thromboembolism in medical inpatients receiving subcutaneous heparin therapy for prophylaxis. *Cor. Art. Dis*. 2012; 23:294-297.
6. Inaba Y, Chen J, **Bergmann SR***. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: A meta-analysis. *Atherosclerosis* 2012; 220:128-133.
7. Kato S, Takahashi K, Ayabe K, Samad R, Fukaya E, Friedmann P, Varma M, **Bergmann SR***. Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. *Br. J. Haematol*. 2011;154: 373-377.
8. Wanahita N, See JL, Giedd KN, Friedmann P, Somekh NN, **Bergmann SR***. No evidence of increased prevalence of premature coronary artery disease in New York City police officers as predicted by coronary artery calcium scoring. *J. Occup. Environ. Med*. 2010; 52: 661-665.
9. Inaba Y, Chen JA, **Bergmann SR***. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. *Int J Cardiovasc Imaging* 2010; 26:631-640.
10. Inaba Y, Chen JA, **Bergmann SR***. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. *J. Nucl. Cardiol*. 2010; 17:646-654.
11. Inaba Y, **Bergmann SR***. Prognostic value of myocardial metabolic imaging with BMIPP in the spectrum of coronary artery disease: a systematic review. *J. Nucl. Cardiol*. 2010; 16:61-70.
12. Ratcliffe JA, Thiagarajah, P, Chen J, Kavala G, Kanei Y, Fox J, Gowda R, Schmitz S, Friedmann P, **Bergmann, SR***. Prevention of contrast-induced nephropathy in high risk patients undergoing coronary angiography and intervention: A randomized controlled trial of sodium bicarbonate and high dose n-acetylcysteine. *Intl. J. Angiol*. 2009; 18:193-197.
13. Inaba Y, Chen JA, Mehta N, **Bergmann SR***. Impact of single or multicentre study design on the results of trials examining the efficacy of adjunctive devices to prevent distal embolization during acute myocardial infarction. *Euro Intervention*. 2009; 5: 375-83.
14. Eslava D, Dhillon S, Berger J, Homel P, **Bergmann SR***. Interpretation of electrocardiograms by first-year residents: the need for change. *J. of Electrocardiology* 2009; 42:693-697.
15. Rosman J, Kavala G, Obunai K, **Bergmann SR***. The Role of Heart-Type Fatty Acid Binding Protein in the Diagnosis of Acute Coronary Syndromes. *Intl. J. Angiology*. 2009; 18: 79-81.
16. Kawut SM, Al-Naamani, N, Agerstaad, C, Rosenzweig, EB, Rowan, C, Barst, RJ, Bergmann, SR, Horn, EM. Determinants of right ventricular ejection fraction in patients with pulmonary arterial hypertension. *Chest*. 2009; 135: 752-759.
17. Kanei Y, Huang Y, Fox JT, Rachko M, **Bergmann SR***. Correlation of antecedent stress myocardial perfusion imaging with the infarct related artery in ST-elevation myocardial infarction. *Int. J. Cardiovasc. Imaging*. 2009; 25:145-149.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

18. Dhillon SK, Rachko M, Hanon S, Schweitzer P, **Bergmann SR***. Telemetry monitoring guidelines for efficient and safe delivery of cardiac rhythm monitoring to non-critical hospital inpatients. *Crit. Pathw. Cardiol.* 2009; 8:125-126.
19. Inaba Y, **Bergmann SR***. Diagnostic accuracy of beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) imaging: a meta-analysis. *J. Nucl. Cardiol.* 2008; 15:345-352.
20. Nichols KJ, Van Tosh A, De Bondt P, **Bergmann SR***, Palestro CJ and Reichek NR. Normal limits of gated blood pool SPECT count-based regional cardiac function parameters. *International Journal of Cardiovascular Imaging.* 2008; 24:715-725.
21. Wysoczanski M, Rachko M, **Bergmann SR***. Acute Myocardial Infarction in a Young Male Using Anabolic Steroids. *Angiology.* 2008; 59:376-378.
22. Bokhari S, Shahzad A, **Bergmann SR***. Superiority of Exercise Myocardial Perfusion Imaging Compared with the Exercise ECG in the Diagnosis of Coronary Artery Disease. *Coronary Artery Disease.* 2008; 19: 399-404.
23. Alhaj EK, Alhaj NE, **Bergmann SR***, Hecht H, Matarazzo TJ, Smith S, Alhaj N, Alhaj M, Nelson S. Coronary artery calcification and emphysema. *Can. J. Cardiol.* 2008; 24:369-372.
24. Somekh NN, Rachko M, Husk G, Friedmann P, **Bergmann SR***. Differences in diagnostic evaluation and clinical outcomes in the care of patients with chest pain based on admitting service: the benefits of a dedicated chest pain unit. *J. Nucl. Cardiol.* 2008; 15:186-192.
25. Arora RR, Bergmann S. Effects of enhanced external counterpulsation (EECP) on myocardial perfusion. *Am. J. Ther.* 2007 Nov-Dec; 14(6):519-23.
26. Nichols KJ, Bacharach SL, **Bergmann SR**, Chen J, Cullom SJ, Dorbala S, Ficaro EP, Galt JR, Green Conaway DL, Heller GV, Hyun MC, Links J, Hyun MC, Machac J. Instrumentation quality assurance and performance. *J. Nucl. Cardiol.* 2007; 13:e61-78.
27. Machac J, Bacharach SL, Bateman TM, Bax JJ, Beanlands R, Bengel F, **Bergmann SR**, Brunken RC, Case J, Delbeke D, DiCarli MF, Garcia EV, Goldstein RA, Gropler RJ, Travin M, Patterson R, Schelbert HR. Positron emission tomography myocardial perfusion and glucose metabolism imaging. *J. Nucl. Cardiol.* 2006; 13:e121-51.
28. Boyle AJ, Whitbourn R, Schlicht S, Krum H, Kocher A, Nandurkar H, **Bergmann SR**, Daniell M, O'Day J, Skerrett D, Haylock D, Gilbert RE, Itescu S. Intra-coronary high dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. *Int. J. Cardiol.* 2006; 109:21-7.
29. Weinsaft JW, Hickey KT, Bokhari S, Shahzad A, Bedding A, Costigan TM, Warner MR, Emmick JT, **Bergmann SR***. Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. *Coronary Artery Disease* 2006; 17:493-499.
30. Rosman J, Shapiro M, Pandey A, Van Tosh A, **Bergmann SR***: Lack of correlation between coronary artery calcium and myocardial perfusion imaging. *J. Nucl. Cardiol.* 2006; 13:333-337.
31. Fridman V, Vandalovsky E, **Bergmann SR***: Cardiac risk factors, medicine usage, and hospital course in immigrants from the former Soviet Union. *J. Health Care for Poor Underserved* 2006; 17:290-301.
32. Biviano AB, Giglio J, Lazar EJ, Cooper M, Sullivan J, Hurley E, Sciacca RR, Tenenbaum J, **Bergmann SR**, Rabbani LE. Positive impact of an interdisciplinary chest pain initiative on traditionally underserved populations. *Crit. Pathw. Cardiol.* 2005; 4:3-9
33. Obunai K, Misra D, VanTosh A, **Bergmann SR***: Metabolic evidence of myocardial stunning in Takotsubo cardiomyopathy: A positron emission tomography study. *J. Nucl. Cardiol.* 2005; 12:742-4.
34. Hickey KT, Sciacca RR, Chou RL, Rodriguez O, Bokhari S, **Bergmann SR***. An improved model for the measurement of myocardial perfusion in human beings using N-13 ammonia. *J. Nucl. Cardiol.* 2005; 12:311-317.
35. Alhaj EK, Pizzarello RA, **Bergmann SR**, Garcia V, Trofimovsky P. A case report of absent right superior vena cava: echocardiographic findings. *J. Am. Soc. Echocardiogr.* 2005; 18:483-5.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

36. Dilsizian V, Bateman TM, **Bergmann SR**, Des Prez R, Magram MY, Goodbody AE, Babich JW, Udelson JE. Metabolic Imaging with beta-methyl-*p*-[(123)I]-Iodophenyl-Pentadecanoic acid identifies ischemic memory after demand ischemia. *Circulation*. 2005; 112:2169-2174.
37. Xydas S, Rosen RS, Pinney S, Hickey KT, Wasserman H, Mancini DM, Naka Y, Oz MC, **Bergmann SR**, Maybaum S. Reduced myocardial blood flow during left ventricular assist device support: A possible cause of premature bypass graft closure. *J. Heart and Lung Transpl.* 2005 Nov; 24(11):1976-1979.
38. Streeter RP, Nichols K, **Bergmann SR***. Stability of right and left ventricular ejection fractions and volumes after heart transplantation. *J. Heart and Lung Transpl.* 2005; 24(7): 815-818.
39. Nichols K, Humayun N, De Bondt P, Vandenberghe S, Akinboboye O, **Bergmann SR**. Model dependence of gated blood pool SPECT ventricular function measurements. *J. Nucl. Cardiol.* 2004; 11(3):282-92.
40. Akinboboye O, Chou R-L, **Bergmann SR**. Myocardial blood flow and mechanical efficiency in concentric and eccentric left ventricular hypertrophy. *Am. J. Hypertens.* 2004; 17:433-438.
41. Hickey KT, Sciacca RR, Bokhari S, Rodriguez O, Chou R-L, Faber TL, Cooke CD, Garcia EV, Nichols K, **Bergmann SR***. Assessment of cardiac wall motion and ejection fraction with gated PET using N-13 ammonia. *Clin. Nucl. Med.* 2004; 29:243-248.
42. Biviano AB, **Bergmann SR**, Tenenbaum J, Sullivan J, Hurley E, Giglio J, Rabbani L. Design of a comprehensive chest pain initiative in an academic urban hospital. *Critical Pathways in Cardiology* 2003; 2:113-117.
43. Shoyeb A, Bokhari S, Sullivan J, Hurley E, Miesner B, Pia R, Giglio J, Sayan OR, Soto L, Chiadika S, LaMarca C, Rabbani LE, **Bergmann SR***. Value of stress myocardial perfusion imaging in the evaluation of patients with chest pain presenting to the emergency department. *Am. J. Cardiol.* 2003; 91:1410-1414.
44. Akinboboye O, Germano G, Idris O, Nichols K, Gopal A, Berman D, **Bergmann SR**. Left ventricular mass measured by myocardial perfusion gated SPECT: Relation to three-dimensional echocardiography. *Clin. Nucl. Med.* 2003; 28:392-397.
45. Akinboboye O, Reichek N, **Bergmann SR**, Chou R-L. Correlates of myocardial oxygen demand measured by positron emission tomography in the hypertrophied left ventricle. *Am. J. Hypertens.* 2003; 16:240-243.
46. Collier LT, Hwang Y, Ramasamy R, Sciacca RR, Hickey KT, Simpson NR, **Bergmann SR***. Synthesis and use of 17-¹¹C-heptadecanoic acid for evaluation of myocardial fatty acid metabolism. *J. Nucl. Med.* 2002; 43:1707-1714.
47. Hwang YC, Bakr S, Ramasamy R, **Bergmann SR***. Relative importance of enhanced glucose uptake versus attenuation of long-chain acyl carnitines in protecting ischemic myocardium. *Coronary Art. Dis.* 2002; 13:313-318.
48. Akinboboye O, Idris O, Goldsmith R, Berekashvili K, Chou R-L, **Bergmann SR**. Positron emission tomography, echo-doppler, and exercise studies of functional capacity in hypertensive heart disease. *Am. J. Hypertens.* 2002; 15:907-910.
49. Bokhari S, **Bergmann SR***. The effect of estrogen compared to estrogen plus progesterone on the exercise electrocardiogram. *J. Am. Coll. Cardiol.* 2002; 40:1092-1096.
50. Nichols K, Kamran M, Cooke CD, Faber TL, Garcia EV, **Bergmann SR**, DePuey EG. Feasibility of detecting cardiac torsion in myocardial perfusion gated SPECT data. *J. Nucl. Card.* 2002; 9:500-507.
51. Akinboboye O, Chou R-L, **Bergmann SR**. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. *J. Am. Coll. Cardiol.* 2002; 40:703-709.
52. Nichols K, Santana CA, Folks R, Krawczynska E, Cooke CD, Faber TL, **Bergmann SR**, Garcia EV. Comparison between ECTb and QGS for assessment of left ventricular function from gated myocardial perfusion SPECT. *J. Nucl. Cardiol.* 2002; 9:285-293.
53. Nichols K, Saouaf R, Ababneh AA, Barst RJ, Rosenbaum MS, Groch MW, **Bergmann SR**: Validation of SPECT equilibrium radionuclide angiographic right ventricular parameters by cardiac magnetic resonance imaging. *J. Nucl. Cardiol.* 2002; 9:153-160.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

54. Maybaum S, Epstein S, Beniaminovitz A, Di Tullio M, Oz M, **Bergmann SR**, Mancini D. Partial loading of the left ventricle during mechanical assist device support is associated with improved mechanical function, blood flow and metabolism and increased exercise capacity. *J. Heart Lung Transplant.* 2002; 21:446-454.
55. Bokhari S, Pinsky DJ, **Bergmann SR***: An improved dobutamine protocol for myocardial perfusion imaging. *Am. J. Cardiol.* 2001; 88:1303-1305.
56. **Bergmann SR***, Herrero P, Sciacca RR, Hartman JJ, Rubin PJ, Hickey KT, Epstein S, Kelly DP: Characterization of altered myocardial fatty acid metabolism in patients with inherited cardiomyopathy. *J. Inherit. Metabol. Dis.* 2001; 24:657-674.
57. Akinboboye OO, Idris O, Onwuanyi A, Berekashvii K, **Bergmann SR**: Incidence of major cardiovascular events in black patients with normal myocardial stress perfusion studies. *J. Nucl. Cardiol.* 2001; 8:541-547.
58. Ramasamy R, Hwang Y, Bakr S, **Bergmann SR**: Protection of ischemic hearts perfused with an anion exchange inhibitor, DIDS, is associated with beneficial changes in substrate metabolism. *Cardiovasc. Res.* 2001; 51:275-282.
59. Ramasamy R, Schaefer S, Whang J, **Bergmann SR**, Payne J: Protection of ischemic myocardium in diabetics by inhibition of the electroneutral $\text{Na}^{++}\text{-K}^{+}\text{-2Cl}^{-}$ co-transporter. *Am. J. Physiol. Heart Circ. Physiol.* 2001; 281:H515-522.
60. Ramasamy R, Hwang YC, Whang J, **Bergmann SR**: Protection of ischemic hearts by high glucose is mediated, in part, by GLUT-4. *Am. J. Physiol. Heart Circ. Physiol.* 2001; 281:H290-H297.
61. Whang J, Ramasamy R, Dizon J, **Bergmann SR***: Enalaprilat attenuates ischemic rises in intracellular sodium in the isolated rat heart via the bradykinin receptor. *J. Cardiovasc. Mag. Res.* 2001; 3:27-34.
62. Bokhari S, Blood DK, **Bergmann SR***: Failure of right precordial electrocardiography during stress testing to identify coronary artery diseases. *J. Nucl. Cardiol.* 2001; 8:325-331.
63. Rohatgi R, Epstein, S, Henriquez J, Ababneh AA, Hickey KT, Pinsky D, Akinboboye O, Bergmann, SR*: Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. *Am. J. Cardiol.* 2001; 87:1096-1099.
64. Lin JW, Laine A, **Bergmann SR***: Improving PET-based physiological quantification through methods of wavelet denoising. *IEEE Transactions on Biomedical Engineering* 2001; 48:202-212.
65. Lin JW, Sciacca R, Chou RL, Laine A, **Bergmann SR***: Quantification of myocardial perfusion in human subjects using rubidium-82 and wavelet-based noise reduction. *J. Nucl. Med.* 2001; 42:201-208.
66. Lin JW, Laine AF, Akinboboye O, **Bergmann SR***: Use of wavelet transforms in the analysis of time-activity data from cardiac PET. *J. Nucl. Med.* 2001; 42:194-200.
67. Sciacca R, Akinboboye O, Chou R, Epstein S, **Bergmann SR***: Measurement of myocardial blood flow with PET using [^{11}C] Acetate. *J. Nucl. Med.* 2001; 42:63-70.
68. Akinboboye O, Idris O, Chou RL, Sciacca RR, Cannon PJ, **Bergmann SR***: Absolute quantitation of coronary steal induced by intravenous dipyridamole. *J. Amer. Coll. Cardiol.* 2001; 37:109-116.
69. Ababneh AA, Sciacca RR, Kim B, **Bergmann SR***: Normal limits for left ventricular ejection fraction and volumes estimated with gated myocardial perfusion imaging in subjects with normal exercise tests: Influence of tracer, gender and acquisition camera. *J. Nucl. Cardiol.* 2000; 7:661-668.
70. Salari S, Ramasamy R, and **Bergmann SR***: Fructose-2, 6-Bisphosphate, a potent stimulator of phosphofruktokinase, is increased by high exogenous glucose perfusion. *Coronary Art. Dis.* 2000; 11:279-286.
71. Akinboboye O, Idris O, Cannon P, and **Bergmann SR***: Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation. *Am. J. Cardiol.* 1999; 83:1271-1274.
72. Rubin PJ, Lee DS, Davila-Roman VG, Geltman EM, Schechtman KB, **Bergmann SR***, Gropler RJ: Superiority of C-11 acetate compared with F-18 fluorodeoxyglucose in predicting myocardial functional

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

- recovery by positron emission tomography in patients with acute myocardial infarction. *Am. J. Cardiol.* 1996; 78:1230-1236.
73. Miller DD, Donohue TJ, Wolford TL, Kern MJ, **Bergmann SR**: Assessment of blood flow distal to coronary artery stenoses: correlations between myocardial positron emission tomography and post-stenotic intracoronary Doppler flow reserve. *Circulation* 1996; 94:2447-2454.
 74. Rubin PJ, Hartman JJ, Hasapes J, Bakke JE, **Bergmann SR***: Detection of cardiac transplant rejection with ¹¹¹In-labeled lymphocytes and gamma scintigraphy. *Circulation*, 94 (Suppl II):II-298-303, 1996.
 75. Herrero P, Hartman JJ, Green MA, Anderson CJ, Welch MJ, Markham J, **Bergmann SR***: Regional myocardial perfusion assessed with generator-produced Copper-62-PTSM and PET. *J. Nucl. Med* 1996; 37:1294-1300.
 76. **Bergmann SR***, Weinheimer CJ, Markham J, Herrero P: Quantitation of myocardial fatty acid metabolism using PET. *J. Nucl. Med.* 1996; 37:1723-1730.
 77. Conversano A, Walsh JF, Geltman EM, Perez JE, **Bergmann SR**, Gropler RJ: Delineation of myocardial stunning and hibernation by positron emission tomography in patients with advanced coronary artery disease. *Am. Heart. J.* 1996; 131:440-450.
 78. De Bruyn VH, **Bergmann SR***, Keyt BA, Bennett WF, Sobel BE: Scintigraphic visualization of pulmonary thrombi with ¹²³I-YPACK-TNK-tPA. *Coronary Artery Dis.* 1995; 6:715-721.
 79. De Bruyn VH, **Bergmann SR***, Keyt BA, Sobel BE: Visualization of thrombi in pulmonary arteries with radiolabeled, enzymatically inactivated tissue-type plasminogen activator. *Circulation* 1995; 92:1320-1325.
 80. Mathias CJ, **Bergmann SR**, Green MA: Species-dependent binding of copper (II) *bis*(thiosemicarbazone) radiopharmaceuticals to serum albumin. *J. Nucl. Med.* 1995; 36:1451-1455.
 81. Herrero P, Staudenerz A, Walsh JF, Gropler RJ, and **Bergmann SR***: Heterogeneity of myocardial perfusion provides the physiological basis of "perfuseable tissue index." *J. Nucl. Med.* 1995; 36:320-327.
 82. Buckman BO, VanBrocklin HF, Dence CS, **Bergmann SR***, Welch MJ, Katzenellenbogen JA: Synthesis and tissue distribution of Ω -[¹¹C]palmitic acid. A novel imaging agent for cardiac metabolism. *J. Med. Chem.* 1994; 37:2481-2485.
 83. Ter-Pogossian MM, Ficke DC, Beecher DE, Hoffman GR, and **Bergmann SR**: The Super PET 3000-E: A PET scanner designed for high count rate cardiac applications. *J. Comput. Assist. Tomogr.* 1994; 18:661-669.
 84. Janier MF, Vanoverschelde JL, **Bergmann SR***: Ischemic preconditioning stimulates anaerobic glycolysis in the isolated rabbit heart. *Am. J. Physiol.: Heart Circ. Physiol.* 1994; 267:H1353-1360.
 85. Vanoverschelde JL, Janier MF, Bakke ME, Marshall DR, **Bergmann SR***: Rate of glycolysis during ischemia determines the extent of ischemic injury and functional recovery following reperfusion. *Am. J. Physiol.: Heart Circ. Physiol.* 1994; 267:H1785-1794.
 86. **Bergmann SR***, Weinheimer CJ, Brown MA, Perez JE: Enhancement of regional myocardial efficiency and persistence of perfusion, oxidative and functional reserve with paired pacing of stunned myocardium. *Circulation* 1994; 89:2290-2296.
 87. Vanoverschelde JL, Janier MF, **Bergmann SR***: The relative importance of myocardial energy metabolism compared with ischemic contracture in the determination of ischemic injury in isolated perfused rabbit hearts. *Circ. Res.* 1994; 74:817-828.
 88. Herrero P, Hartman JJ, Senneff MJ, **Bergmann SR***: Effects of time discrepancies between input and myocardial time-activity curves on estimates of regional myocardial perfusion with PET. *J. Nucl. Med.* 1994; 35:558-566.
 89. Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Conversano A, Sobel BE, **Bergmann SR**: Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. *J. Am. Coll. Cardiol.* 1993; 22:1587-1597.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

90. Shelton ME, Senneff MJ, Ludbrook PA, Sobel BE, **Bergmann SR***: Concordance of nutritive myocardial perfusion reserve and flow velocity reserve in conductance vessels in patients with chest pain with angiographically normal coronary arteries. *J. Nucl. Med.* 1993; 34:717-722.
91. Weinheimer CJ, Brown MA, Nohara R, Perez JE, **Bergmann SR***: Functional recovery after reperfusion is predicated on recovery of myocardial oxidative metabolism. *Am. Heart J.* 1993; 125:939-949.
92. Mathias CJ, **Bergmann SR**, Green MA: Development and validation of a solvent extraction technique for determination of Cu-PTSM in blood. *Nucl. Med. Biol.* 1993; 20:343-349.
93. Kelly DP, Mendelsohn NJ, Sobel BE, **Bergmann SR***: Detection and assessment by positron emission tomography of a genetically determined defect in myocardial fatty acid utilization (long-chain acyl-CoA dehydrogenase deficiency). *Am. J. Cardiol.* 1993; 71:738-744.
94. Senneff MJ, Hartman JJ, Sobel BE, Geltman EM, **Bergmann SR***: Persistence of coronary vasodilator responsivity after cardiac transplantation. *Am. J. Cardiol.* 1993; 71:333-338.
95. Janier MF, Vanoverschelde JL, **Bergmann SR***: Adenosine protects ischemic and reperfused myocardium by receptor-mediated mechanisms. *Am. J. Physiol.: Heart Circ. Physiol.* 1993; 264:H163-H170.
96. Herrero P, Markham J, Weinheimer CJ, Anderson CJ, Welch MJ, Green MA, **Bergmann SR***: Quantification of regional myocardial perfusion with generator-produced ⁶²Cu-PTSM and positron emission tomography. *Circulation* 1993; 87:173-183.
97. Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Moerlein SM, Sobel BE, **Bergmann SR***, Siegel BA: Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. *J. Am. Coll. Cardiol.* 1992; 20:569-577.
98. Herrero P, Markham J, Shelton ME, and **Bergmann SR***: Implementation and evaluation of a two-compartment model for quantification of myocardial perfusion with rubidium-82 and positron emission tomography. *Circ. Res.* 1992; 70:496-507.
99. Weinheimer CJ, Toeniskoetter PD, Conversano A, Pelat P, Dubourg AY, **Bergmann SR***: Pretreatment with buflomedil enhances ventricular function by reducing the dysfunctional area after transient coronary artery occlusion. *Cardiovasc. Res.* 1992; 26:470-475.
100. Gropler RJ, Siegel BA, Sampathkumaran K, Perez JE, Sobel BE, **Bergmann SR***, Geltman EM: Dependence of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. *J. Am. Coll. Cardiol.* 1992; 19:989-997.
101. Ord JM, Hasapes J, Daugherty A, Thorpe SR, **Bergmann SR**, Sobel BE: Imaging of thrombi with tissue-type plasminogen activator rendered enzymatically inactive and conjugated to a residualizing label. *Circulation* 1992; 85:288-297.
102. Senneff MJ, Geltman EM, **Bergmann SR***: Noninvasive delineation of the effects of moderate aging on myocardial perfusion. *J. Nucl. Med.* 1991; 32:2037-2042.
103. Torr SR*, Haskel EJ, VonVoigtlander PF, **Bergmann SR***, Abendschein DR: Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor. *J. Am. Coll. Cardiol.* 1991; 18:1804-1810.
104. Koller PT, **Bergmann SR***: Neutrophil-mediated myocardial injury in isolated perfused rabbit hearts. *Coronary Artery Dis.* 1991; 2:691-698.
105. Mathias CJ, Welch MJ, Green MA, Diril H, Meares CF, Gropler RJ, **Bergmann SR***: In vivo comparison of copper blood-pool agents: potential radiopharmaceuticals for use with copper-62. *J. Nucl. Med.* 1991; 32:475-480.
106. Weinheimer CJ, James HL, Kalyan NK, Wilhelm J, Lee SG, Hung PP, Sobel BE, **Bergmann SR***: Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. *Circulation* 1991; 83:1429-1436.
107. Henes CG, **Bergmann SR***, Perez JE, Sobel BE, Geltman EM: The time course of restoration of nutritive perfusion, myocardial oxygen consumption, and regional function after coronary thrombolysis. *Coronary Artery Dis.* 1990; 1:687-69.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

108. Green MA, Mathias CJ, Welch MJ, McGuire AH, Perry D, Fernandez-Rubio F, Perlmutter JS, Raichle ME, **Bergmann SR**: Copper-62-labeled pyruvaldehyde *Bis*(N⁴-methylthiosemicarbazone) copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. *J. Nucl. Med.* 1990; 31:1989-1996.
109. Miller TR, Wallis JW, Geltman EM, **Bergmann SR**: Three-dimensional functional images of myocardial oxygen consumption from positron tomography. *J. Nucl. Med.* 1990; 31:2064-2068.
110. Geltman EM, Henes CG, Senneff MJ, Sobel BE, **Bergmann SR***: Increased myocardial perfusion at rest and diminished perfusion reserve in patients with angina and angiographically normal coronary arteries. *J. Am. Coll. Cardiol.* 1990; 16:586-595.
111. Herrero P, Markham J, Shelton ME, Weinheimer CJ, and **Bergmann SR***: Noninvasive quantitation of regional myocardial blood flow with rubidium-82 and positron emission tomography: exploration of a mathematical model. *Circulation* 1990; 82:1377-1386.
112. Sobel BE, Nachowiak DA, Fry ETA, **Bergmann SR**, Torr SR: Paradoxical attenuation of fibrinolysis attributable to "plasminogen steal" and its implications for coronary thrombolysis. *Coronary Artery Dis.* 1990; 1:111-119.
113. Shelton ME, Green MA, Mathias CJ, Welch MJ, **Bergmann SR***: Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography. *Circulation* 1990; 82:990-997.
114. Shelton ME, Dence CS, Hwang D-R, Herrero P, Welch MJ, **Bergmann SR***: In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. *J. Am. Coll. Cardiol.* 1990; 16:477-485.
115. Nohara R, **Bergmann SR***: Reduction of stenosis-induced cyclic flow variations by inhibition of platelet-activating factor in dogs. *Coronary Artery Dis.* 1990; 1:347-354.
116. Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, **Bergmann SR**, Geltman EM: Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxy-glucose in normal fasted humans. *J. Nucl. Med.* 1990; 31:1749-1756.
117. Walsh MN, Geltman EM, Steele RL, Kenzora JL, Ludbrook PA, Sobel BE, **Bergmann SR***: Augmented myocardial perfusion reserve after coronary angioplasty quantified by positron emission tomography with H₂¹⁵O. *J. Am. Coll. Cardiol.* 1990; 15:119-127.
118. Walsh MN, Geltman EM, Brown MA, Henes CG, Weinheimer CJ, Sobel BE, **Bergmann SR***: Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction. *J. Nucl. Med.* 1989; 30:1798-1808.
119. Shelton ME, Green MA, Mathias CJ, Welch MJ, **Bergmann SR***: Kinetics of copper-PTSM in isolated hearts: a novel tracer for measuring blood flow with positron emission tomography. *J. Nucl. Med.* 1989; 30:1843-1847.
120. Shelton ME, Dence CS, Hwang DR, Welch MJ, **Bergmann SR***: Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. *J. Nucl. Med.* 1989; 30:351-358.
121. Nohara R, Abendschein DR, **Bergmann SR***: Transmural gradients of coronary flow reserve with physiologically and morphometrically defined stenoses in dogs. *Am. Heart J.* 1989; 118:1167-75.
122. Koller PT, **Bergmann SR***: Reduction of lipid peroxidation in reperfused isolated rabbit hearts by diltiazem. *Circ. Res.* 1989; 65:838-846.
123. Herrero P, Markham J, **Bergmann SR***: Quantitation of myocardial blood flow with H₂¹⁵O and positron emission tomography: assessment and error analysis of a mathematical approach. *J. Comp. Assist. Tomogr.* 1989; 13:862-873.
124. Henes GC, **Bergmann SR***, Walsh MN, Sobel BE, Geltman EM: Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate. *J. Nucl. Med.* 1989; 30:1489-1499.
125. Brown MA, Myears DW, and **Bergmann SR***: Validity of estimates of myocardial oxidative metabolism

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

- with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization. *J. Nucl. Med.* 1989; 30:187-193.
126. **Bergmann SR***, Herrero P, Markham J, Weinheimer CJ, Walsh MN: Non-invasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. *J. Am. Coll. Cardiol.* 1989; 14:639-652.
 127. Walsh MN, **Bergmann SR***, Steele RL, Kenzora JL, Ter-Pogossian MM, Sobel BE, Geltman EM: Delineation of impaired regional myocardial perfusion by positron emission tomography with H₂¹⁵O. *Circulation* 1988; 78:612-620.
 128. Rosenbloom M, Eisen HJ, Laschinger J, Saffitz JE, Sobel BE, **Bergmann SR***, Bolman RM: Non-invasive assessment of treatment of cardiac allograft rejection with indium-111 labeled lymphocytes. *Transplantation* 1988; 46:341-346.
 129. Myears DW, Nohara R, Abendschein DR, Saffitz JE, Sobel BE, **Bergmann SR***: Compromise of beneficial effects of reperfusion on myocardium supplied by vessels with critical residual stenosis. *J. Am. Coll. Cardiol.* 1988; 11:1078-1086.
 130. Herrero P, Markham J, Myears DW, Weinheimer CJ, **Bergmann SR***: Measurement of myocardial blood flow with positron emission tomography: correction for count spillover and partial volume effects. *Mathl. Comput. Modelling* 1988; 11:807-812.
 131. Eisenberg SB, Eisen HJ, Sobel BE, **Bergmann SR***, Bolman RM: Sensitivity of scintigraphy with ¹¹¹In-lymphocytes for detection of cardiac allograft rejection. *J. Surg. Res.* 1988; 45:549-555.
 132. Eisen HJ, Rosenbloom M, Laschinger JC, Saffitz JE, Cox JL, Sobel BE, Bolman RM, **Bergmann SR***: Detection of rejection of canine orthotopic cardiac allografts with indium-111 lymphocytes and gamma scintigraphy. *J. Nucl. Med.* 1988; 29:1223-1229.
 133. Brown MA, Myears DW, **Bergmann SR***: Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography. *J. Am. Coll. Cardiol.* 1988; 12:1054-1063.
 134. Rosenbloom M, Eisen HJ, Eisenberg SB, Laschinger JC, Saffitz JE, **Bergmann SR**, Sobel BE, Cox JL, Bolman RM. Sensitivity of scintigraphy with 111-indium-labeled lymphocytes for noninvasive detection of cardiac allograft rejection. *Surgical Forum.* 1987; 38:290.
 135. Rosamond TL, Abendschein DR, Sobel BE, **Bergmann SR***, and Fox KAA: Metabolic fate of radiolabeled palmitate in ischemic canine myocardium: implications for positron emission tomography. *J. Nucl. Med.* 1987; 28:1322-1329.
 136. Myears DW, Sobel BE, **Bergmann SR***: Substrate use in ischemic and reperfused canine myocardium: quantitative considerations. *Am. J. Physiol.: Heart Circ. Physiol.* 1987; 253:H107-H114.
 137. Knabb RM, **Bergmann SR***, Fox KAA, Sobel BE: The temporal pattern of recovery of myocardial perfusion and metabolism delineated by positron emission tomography after coronary thrombolysis. *J. Nucl. Med.* 1987; 28:1563-1570.
 138. Eisen HJ, Eisenberg SB, Saffitz JE, Bolman RM, Sobel BE, and **Bergmann SR***: Non-invasive detection of rejection of transplanted hearts with indium-111 labeled lymphocytes. *Circulation* 1987; 75:868-876.
 139. Brown MA, Marshall DR, Sobel BE, and **Bergmann SR***: Delineation of myocardial oxygen utilization with carbon-11 labeled acetate. *Circulation* 1987; 76:687-696.
 140. Abendschein DR, Fox KAA, Ambos HD, Sobel BE, **Bergmann SR***: Metabolism of beta-methyl[1-¹¹C]heptadecanoic acid in canine myocardium. *Int'l. J. Radiat. Appl. Instrum., Nucl. Med. Biol.* 1987; 14:579-585.
 141. Knabb RM, Rosamond TL, Fox KAA, Sobel BE, **Bergmann SR***: Enhancement of salvage of reperfused ischemic myocardium by diltiazem. *J. Am. Coll. Cardiol.* 1986; 8:861-871.
 142. Hughes B, Marshall DR, Sobel BE, **Bergmann SR***: Characterization of beta-adrenoreceptors in vivo with iodine-131 pindolol and gamma scintigraphy. *J. Nucl. Med.* 1986; 27:660-667.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

143. Hughes B, **Bergmann SR***, Corr PB, Sobel BE: External detection of β -adrenoceptors with ^{125}I -hydroxybenzylpindolol in isolated perfused hearts. *Int'l. J. Nucl. Med. Biol.* 1986; 13:565-571.
144. Fields LE, Daugherty A, **Bergmann SR***: Effect of fatty acid on performance and lipid content of hearts from diabetic rabbits. *Am. J. Physiol.: Heart Circ. Physiol.* 1986; 250:H1079-H1085.
145. Knabb RM, Fox KAA, Sobel BE, **Bergmann SR***: Characterization of the functional significance of subcritical coronary stenoses with H_2^{150} and positron-emission tomography. *Circulation* 1985; 71:1271-1278.
146. Fox KAA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, and **Bergmann SR***: Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. *Circulation* 1985; 72:1346-1354.
147. Fox KAA, Abendschein D, Ambos HD, Sobel BE, **Bergmann SR***: Efflux of metabolized and nonmetabolized fatty acid from canine myocardium. Implications for quantifying myocardial metabolism tomographically. *Circ. Res.* 1985; 57:232-243.
148. **Bergmann SR***, Angelakos ET, Torres JC: Salutory effects of moderate hypothermia on the circulatory and myocardial consequences of acute coronary occlusion in dogs. *Cryobiology* 1985; 22:555-568.
149. Van de Werf F, Ludbrook PA, **Bergmann SR**, Tiefenbrunn AJ, Fox KAA, De Geest H, Verstraete M, Collen D, Sobel BE: Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. *N. Engl. J. Med.* 1984; 310: 609-613.
150. Van de Werf F, **Bergmann SR**, Fox KAA, De Geest H, Hoyng CF, Sobel BE, Collen D: Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. *Circulation* 1984; 69:605-610.
151. Kenzora JL, Perez JE, **Bergmann SR**, Lange LG: Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. *J. Clin. Invest.* 1984; 74:1193-1203.
152. Fox KAA, **Bergmann SR***, Mathias CJ, Powers WJ, Siegel BA, Welch MJ, Sobel BE: Scintigraphic detection of coronary artery thrombi in patients with acute myocardial infarction. *J. Am. Coll. Cardiol.* 1984; 4:975-986.
153. **Bergmann SR***, Fox KAA, Rand AL, McElvany KD, Welch MJ, Markham J, Sobel BE: Quantification of regional myocardial blood flow in vivo with H_2^{150} . *Circulation* 1984; 70:724-733.
154. Hack SN, **Bergmann SR***, Eichling JO, Sobel BE: Quantification of regional myocardial perfusion by exponential infusion of ^{11}C -butanol. *IEEE Trans. on Biomed. Eng.* 1983; BME-30:716-722.
155. Fox KAA, Nomura H, Sobel BE, **Bergmann SR***: Consistent substrate utilization despite reduced flow in hearts with maintained work. *Am. J. Physiol.:Heart Circ. Physiol.* 1983; 244:H799-H806.
156. **Bergmann SR***, Lerch RA, Mathias CJ, Sobel BE, Welch MJ: Non-invasive detection of coronary thrombi with ^{111}In -platelets. *J. Nucl. Med.* 1983; 24:130-135.
157. **Bergmann SR***, Fox KAA, Ter-Pogossian MM, Sobel BE, Collen D: Clot-selective coronary thrombolysis with tissue-type plasminogen activator. *Science* 1983; 220:1181-1183.
158. Ter-Pogossian MM, **Bergmann SR**, Sobel BE: Influence of cardiac and respiratory motion on tomographic reconstructions of the heart: implications for quantitative nuclear cardiology. *J. Comp. Assist. Tomogr.* 1982; 6:1148-1155.
159. Lerch RA, **Bergmann SR***, Carlson EM, Saffitz JE, Sobel BE: Monitoring of cardiac antirejection therapy with In-111 lymphocytes. *J. Nucl. Med.* 1982; 23:496-500.
160. Lerch RA, **Bergmann SR***, Ambos HD, Welch MJ, Ter-Pogossian MM, Sobel BE: Effect of flow-independent reduction of metabolism on regional myocardial clearance of ^{11}C -palmitate. *Circulation* 1982; 65:731-738.
161. Lerch RA, Ambos HD, **Bergmann SR***, Sobel BE, Ter-Pogossian MM: Kinetics of positron emitters in vivo characterized with a beta-probe. *Am. J. Physiol.: Heart Circ. Physiol.* 1982; 242:H62-H67.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

162. **Bergmann SR***, Mathias CJ, Sobel BE, Welch MJ: Evaluation of thrombolytic therapy in coronary artery thrombosis: scintigraphic detection with the use of In-111-labeled platelets. Proceedings of the Third World Congress of Nuclear Medicine and Biology, C. Raymond, Ed., Pergamon Press, Paris, 1982, p. 65-68.
163. **Bergmann SR***, Lerch RA, Fox KAA, Ludbrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE: Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am. J. Med. 1982; 73:573-581.
164. **Bergmann SR***, Lerch RA, Carlson EM, Saffitz JE, Sobel BE: Detection of cardiac transplant rejection with radiolabeled lymphocytes. Circulation 1982; 65:591-599.
165. **Bergmann SR***, Hack SN, Sobel BE: Redistribution of myocardial thallium-201 without reperfusion: implications regarding absolute quantification of perfusion. Am. J. Cardiol. 1982; 49:1691-1698.
166. Lerch RA, Ambos HD, **Bergmann SR***, Welch MJ, Ter-Pogossian MM, Sobel BE: Localization of viable but ischemic myocardium by positron emission tomography (PET) with ¹¹C-palmitate. Circulation 1981; 64:689-699.
167. Lange LG, **Bergmann SR**, Sobel BE: Identification of fatty acid ethyl esters as products of rabbit myocardial ethanol metabolism. J. Biol. Chem. 1981; 256:12968-12973.
168. **Bergmann SR***, Ferguson Jr TB, Sobel BE: Effects of amphiphiles on erythrocytes, coronary arteries and perfused hearts. Am. J. Physiol. 1981; 240:H229-H237.
169. Hack S, Eichling JO, **Bergmann SR***, Sobel BE: External quantification of myocardial perfusion by exponential infusion of positron emitting radionuclides. J. Clin. Invest. 1980; 66:918-927.
170. Hack SN, **Bergmann SR***, Sobel BE: Microcomputer based instrumentation for a tracer kinetics laboratory. Computers in Cardiology. IEEE Computer Society, Long Beach, 1980, p. 427-430.
171. **Bergmann SR***, Hack S, Tewson TJ, Welch MJ, Sobel BE: The dependence of accumulation of ¹³NH₃ by myocardium on metabolic factors and its implications for quantitative assessment of perfusion. Circulation 1980; 61:34-43.
172. **Bergmann SR***, Carlson E, Dannen E, Sobel BE: An improved assay with 4-(2-thiazolylazo)-resorcinol for free fatty acids in biological fluids. Clinica Chimica Acta 1980; 104:53-63.
173. **Bergmann SR***, Clark RE, Sobel BE: An improved isolated heart preparation for external assessment of myocardial metabolism. Am. J. Physiol.: Heart Circ. Physiol. 1979; 236:H644-H651.
174. Ahumada GG, **Bergmann SR**, Carlson E, Corr PB, Sobel BE: Augmentation of cyclic AMP content induced by lysophosphatidyl choline in rabbit hearts. Cardiovasc. Res. 1979; 13:377-382.

Invited Reviews and Book Chapters

1. Kim AS and **Bergmann SR**. Anthracycline induced cardiomyopathy. The search continues. J. Nucl. Cardiol. 2017; 24:265-267.
2. Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, Gropler RJ, Knuuti J, Schelbert HR, Travin MI. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016; 23:1187-1226.
3. Karimeddini D and **Bergmann SR**. The state of the future is solid. J. Nucl. Cardiol. 2015; 23:1288-1290.
4. Braunwald E, Cohen LS, Roberts R, **Bergmann SR**, Jaffe AS, Fujii S. Burton Elias Sobel (1937–2013): His friends speak. Am. J. Cardiol. 2014; 113:402-405.
5. Schneider DJ, Avera ES, **Bergmann SR**, Braunwald E, Collen D, Frye R, Jaffe A, Kirk R, Ludbrook PA, Roberts R, Spector P, Vlasuk GP, Willerson JT. In memoriam: Burton E. Sobel. A Tribute from family, friends and colleagues. Exp. Biol. Med. 2013; 238:1101-1115.
6. Giedd KN, **Bergmann SR***. Fatty acid imaging of the heart. Curr. Cardiol. Rep. 2011; 13:121-131.
7. Dilsizian V, Bacharach SL, Beanlands RS, **Bergmann SR**, Delbeke D, Gropler RJ, Knuuti J, Schelbert HR, Travin MI. PET myocardial perfusion and metabolism clinical imaging. J. Nucl. Cardiol. 2009; 16:651.
8. Bergmann, SR*. Imaging of Myocardial Fatty Acid Metabolism. J. Nucl. Cardiol. 2007; 14:S118-124.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

9. Jani S, **Bergmann SR***: Metabolic Modulation of Myocardial Ischemia. *Curr. Cardiol. Rep.* 2006; 8:123-130.
10. Travin MI, **Bergmann SR**. Assessment of myocardial viability. In: *Semin. Nucl. Med.* 2005; 35:2-16.
11. Gibson CM, Grayburn PA, Di Carli MF, Dorbala S, Li D, Deshpande VS, Wilke N, Raff GL, Panse PM, **Bergmann SR**: Quantitation of Myocardial Perfusion. In: Clinical Cardiovascular Imaging: A Companion to Braunwald's Heart Disease, M St. John Sutton, JD Rutherford, J Leppo, Eds. W.B. Saunders Company, Philadelphia, PA 2004; 105-145.
12. Giedd KN and **Bergmann SR***: Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. *J. Am. Coll. Cardiol.* 2004; 43: 328-36.
13. Beller, GA and **Bergmann SR**: Myocardial Perfusion Imaging Agents: SPECT and PET. *J. Nucl. Cardiol.* 2004; 71-86.
14. Hwang DR and **Bergmann SR***. Radiopharmaceuticals for studying the heart. In: Handbook of Radiopharmaceuticals: radiochemistry and applications. MJ Welch and CS Redvanly, Eds. John Wiley and Sons Ltd. West Sussex, England 2003; 529-555.
15. Epstein S and **Bergmann SR***: Noninvasive assessment of inherited cardiac disease using positron emission tomography. In: Molecular Nuclear Medicine, L Feinendegen, YW Bahk, WW Shreeve, HN Wagner, Eds. Ecomed Publishers, Landsberg, Germany 2003; 411-421.
16. **Bergmann SR***, Giedd KN. Silent ischemia: Unsafe at any time. (Editorial). *J. Am. Coll. Cardiol.* 2003; 42:41-44.
17. Bokhari S, **Bergmann SR***. Imaging of myocardial fatty acid metabolism with positron emission tomography. *Medical Imaging International.* 2003; 13:6-8.
18. Lazar EJ and **Bergmann SR**: New drug development and FDA approval. In: *Cardiovascular Pharmacotherapeutics*, WH Frishman, EH Sonnenblick, and DA Sica, Eds., McGraw-Hill, New York, NY 2002; 35-41.
19. Ramasamy R and **Bergmann SR***: Adjunctive protection of ischemic myocardium by modification of metabolism. In: Challenges in Acute Coronary Syndromes, DP de Bono and BE Sobel, Eds., Blackwell Science, Oxford, England 2000; 253-268.
20. DeGrado, TR, **Bergmann SR**, Ng CK, Raffel DM: Tracer kinetic modeling in nuclear cardiology. *J. Nucl. Cardiol.* 2000; 7:686-700.
21. Akinboboye O, **Bergmann SR***. Use of carbon 11-acetate for the measurement of myocardial oxygen consumption. *J. Nucl. Cardiol.* 2000; 7:282-285.
22. Nichols K and **Bergmann SR***: Use of perfusion agents to measure cardiac output. (Editorial) *J. Nucl. Med.* 1999; 40:1882-1883.
23. **Bergmann SR***: Cardiac positron emission tomography. *Semin. Nucl. Med.* 1998; 28: 320-340.
24. **Bergmann SR***: Positron emission tomography of the heart. In: Cardiac Nuclear Medicine - Third Edition, MC Gerson, Ed., McGraw-Hill, New York, NY 1997; 267-299.
25. **Bergmann SR***: Clinical applications of myocardial perfusion assessments made with oxygen-15 water and positron emission tomography. *Cardiology*, 1997; 88:71-79.
26. **Bergmann SR***: Imaging of the heart: potential application to alcohol-induced heart disease. *Alcohol & Health Research World* 1996; 19:287-292.
27. Rubin PR, **Bergmann SR***: Assessment of myocardial viability with positron emission tomography after coronary thrombolysis. In: Imaging and Intervention in Cardiology. C.A. Nienaber, Editor. Kluwer Academic Publishers, Inc., the Netherlands 1996; 43-52.
28. Herrero P, **Bergmann SR***: Assessment of myocardial perfusion with oxygen-15 labeled water and positron emission tomography. In: Cardiac PET. M. Schwaiger, Editor. Kluwer Academic Publishers, Inc., Norwell, Massachusetts 1996; 147-160.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

29. **Bergmann SR***: Delineation of viable myocardium with metabolic imaging. In: Myocardial Viability: Detection and Clinical Relevance. A.S. Iskandrian and E.E. van der Wall, Editors. Kluwer Academic Publishers, Inc., Dordrecht, the Netherlands 1994; 53-70.
30. Anderson CJ, **Bergmann SR***: In search of the perfect PET flow tracer. (Editorial) J. Nucl. Med. 1994; 35:1122-1124.
31. **Bergmann SR***: Use and limitations of metabolic tracers labeled with positron-emitting radionuclides in the identification of viable myocardium. J. Nucl. Med. 1994; 35(Suppl):15S-22S.
32. **Bergmann SR***: Imaging of the heart with positron emission tomography. Am. J. Card. Imag. 1994; 8:181-188.
33. Conversano A, **Bergmann SR***: Use of positron emission tomography for evaluating myocardial perfusion and oxygen consumption after coronary recanalization. In: Nuclear Cardiology: The State of the Art and Future Directions. B.L. Zaret and G. Beller, Editors. The C.V. Mosby Company, St. Louis, Missouri 1993; 275-283.
34. Vanoverschelde JL, **Bergmann SR***: Myocardial reperfusion injury. Concepts, mechanisms, and therapeutic strategies. In: Coronary Thrombolysis in Perspective. B.E. Sobel and D. Collen, Editors. Marcel Dekker, Inc., New York, New York 1993; 271-301.
35. Gropler RJ, **Bergmann SR***: Flow and metabolic determinants of myocardial viability assessed by positron-emission tomography. Coronary Artery Dis. 1993; 4:495-504.
36. **Bergmann SR***: Positron emission tomography of the heart: a look forward. Cardiology 1993; 1:16-19.
37. **Bergmann SR***: Positron emission tomography in cardiology: a clinical procedure, a research tool, or both? (editorial) Coronary Artery Dis. 1992; 3:439-442.
38. Lerch RA, **Bergmann SR***, Sobel BE: Delineation of myocardial fatty acid metabolism with positron emission tomography. In: Positron Emission Tomography of the Heart. S.R. Bergmann and B.E. Sobel, Editors. Futura Publishing, Inc., Mount Kisco, New York, 1992; 129-152.
39. **Bergmann SR***, Sobel BE: Quantification of regional myocardial oxidative utilization by positron emission tomography. In: Positron Emission Tomography of the Heart. S.R. Bergmann and B.E. Sobel, Editors. Futura Publishing, Inc., Mount Kisco, New York 1992; 209-229.
40. **Bergmann SR***: Quantification of myocardial perfusion with positron emission tomography. In: Positron Emission Tomography of the Heart. S.R. Bergmann and B.E. Sobel, Editors. Futura Publishing, Inc., Mount Kisco, New York 1992; 97-127.
41. Herrero P, **Bergmann SR***: Quantification of myocardial perfusion with oxygen-15 water. In: What's New In Cardiac Imaging? SPECT, PET, and MRI. E.E. van der Wall, H. Sochor, A. Righetti, and M.G. Niemeyer, Editors. Kluwer Academic Publishers, the Netherlands 1992; 157-164.
42. Gropler RJ, **Bergmann SR***: Myocardial viability--what is the definition? (Editorial) J. Nucl. Med. 1991; 32:10-12.
43. **Bergmann SR***: Quantitation of myocardial perfusion in human subjects with positron emission tomography. In: Imaging, Measurements, and Analysis of the Heart. S. Sideman and R. Beyar, Editors. Hemisphere Publishing Corp., Washington, D.C. 1991; 241-254.
44. Janier M, **Bergmann SR***: The role of calcium-channel antagonists in reperfusion. The Age of Reperfusion 1990; 2:5-7.
45. Hung P, Wilhelm J, Kalyan NK, Cheng SM, James HL, Nachowiak D, Weinheimer CJ, Sobel BE, **Bergmann SR***, Lee SG: Biological properties of hybrid plasminogen activators. In: Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis. C.Y. Liu and S. Chien, Editors. Plenum Press, New York 1990; 201-208.
46. Herrero P, **Bergmann SR***: Recent developments in quantification of myocardial perfusion with positron emission tomography. Coronary Artery Dis. 1990; 1:518-525.
47. **Bergmann SR***: Positron emission tomography of the heart. In: Cardiac Nuclear Medicine, Second

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Edition. M. Gerson, Editor. McGraw-Hill, New York 1990; 299-335.

48. **Bergmann SR***, Sobel BE: Surgical recanalization for treatment of evolving myocardial infarction. (Editorial) *Ann. Thor. Surgery* 1989; 48:319-321.
49. **Bergmann SR**, Sobel BE: Angioplasty after thrombolysis in the treatment of evolving myocardial infarction. *Biomed. and Pharmacother.* 1989; 43:107-112.
50. **Bergmann SR**, Sobel BE: Noninvasive assessment of the efficacy of coronary thrombolysis. In: Thrombolysis in Cardiovascular Disease. D. Julian, W. Kubler, R.N. Norris, H.J.C. Swan, D. Collen, and M. Verstraete, Editors. Marcel Dekker, Inc., New York 1989; 141-161.
51. **Bergmann SR***: Clinical applications of assessments of myocardial substrate utilization with positron emission tomography. *Mol. Cell. Biochem.* 1989; 88:201-209.
52. Lerch RA, **Bergmann SR***: Non-invasive assessment of myocardial fatty acid metabolism with positron emission tomography and gamma imaging. James L. Ritchie, Editor. In: New Concepts in Cardiac Imaging 1988, Year Book Medical Publishers, Chicago 1988; 91-116.
53. Fox KAA, Knabb RM, **Bergmann SR**, Sobel BE: Progress in cardiac positron emission tomography with emphasis on carbon-11 labeled palmitate and oxygen-15 labeled water. In: Noninvasive Imaging of Cardiac Metabolism, E.E. Van der Wall, Editor. Martinus Nijhoff Publishers, Boston 1987; 203-240.
54. **Bergmann SR***, Ludbrook PA, Sobel BE: Coronary thrombolysis with tissue-type plasminogen activator. *Cardiology Clinics* 1987; 5:101-111.
55. **Bergmann SR***, Fox KAA, Ludbrook PA: Determinants of salvage of jeopardized myocardium after coronary thrombolysis. *Cardiology Clinics* 1987; 5:67-77.
56. Sobel BE, **Bergmann SR**: The impact of coronary thrombolysis and tissue-type plasminogen activator (t-PA) on acute myocardial infarction. In: Thrombolysis: Biological and therapeutic properties of new thrombolytic agents. D. Collen, H.R. Lijnen, and M. Verstraete, Eds. Churchill Livingstone, Edinburgh 1985; 61-84.
57. Sobel BE, **Bergmann SR**: Coronary thrombolysis: some unresolved issues. (Editorial) *Am. J. Med.* 1982; 72:1-4.
58. Sobel BE, **Bergmann SR**: Cardiac positron emission tomography. *Int'l. J. Cardiol.* 1982; 2:273-277.
59. **Bergmann SR***, Ter-Pogossian MM, Sobel BE: Biomedical Applications of Positron Emission Tomography. In: Cardiovascular Instrumentation: Applicability of New Technology to Bio-behavioral Research. J.A. Herd, A.M. Gotto, P.G. Kaufmann, S.M. Weiss, Eds., NIH, 1984; 239-247.
60. Fox KAA, **Bergmann SR**, Sobel BE: Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA). *Bio-chem. Pharmacol.* 1984; 33:1831-1838.
61. Sobel BE, Geltman EM, **Bergmann SR**: Quantitative assessment of infarct size and its influence by thrombolysis. In: Cardiology. E.I. Chazov, V.N. Smirnov, and R.G. Oganov, Eds. Plenum Publishing, New York 1984; 525-533.
62. **Bergmann SR***, Fox KAA, Geltman EM, Sobel BE: Positron emission tomography of the heart. *Prog. Cardiovascular Dis.* 1985; 28:165-194.
63. Fox KAA, **Bergmann SR**, Sobel BE: Pathophysiology of myocardial reperfusion. *Ann. Rev. Med.* 1985; 36:125-144.
64. Lerch R, **Bergmann SR***: Assessment of myocardial metabolism with ¹¹C-palmitate. Comparison with ¹²³I-heptadecanoic acid. *Eur. Heart J.* 1985; 6 (Supl. B), 21-27.
65. Geltman EM, **Bergmann SR**, Sobel BE: Cardiac positron emission tomography. In: Positron Emission Tomography. M. Reivich and A. Alavi, Eds. Alan R. Liss, New York 1985; 345-385.

Books

1. **Bergmann SR**, Sobel BE, Editors. Positron emission tomography of the heart. Futura Publishing, Inc., Mount Kisco, New York, 1992.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Poetry

1. Bergmann, SR. No code here. Anastomoses. Feb 12, 2015. <http://www.anastomoseslitmag.com/poetry-1/2015/2/12/no-code-here-steven-r-bergmann-md-phd>

Letters to the Editor

1. Inaba, Y., Chen, JA, **Bergmann SR**. Carotid intima-media thickness and cardiovascular events. *N. Engl. J. Med.* 2011; 365: 1640-1641
2. Bergmann, S.R.*: Letter to the Editor: Aggrenox® and stress testing. (Letter) *Circulation* 103:E50, 2001.
3. Bokhari, S., Bergmann, S.R.*: Warning to physicians performing pharmacologic stress tests. (Letter) *J. Nucl. Cardiol.* 7:546, 2000.
4. Bergmann, S.R.*: Alert to physicians: Possible interaction of Aggrenox® and adenosine. (Letter) *J. Am. Coll. Cardiol.* 36:1432, 2000.
5. Bokhari, S., Blood, D.K., Bergmann, S.R.*: Use of right precordial leads during exercise testing. [Letter] *N. Engl. J. Med.* 343:968-969, 2000.
6. Bergmann, S.R.*, Herrero, P., and Geltman, E.M.: Blunted response of myocardial perfusion to dipyridamole in older adults (Revisited). (Letter) *J. Nucl. Med.* 36:1137-1139, 1995.
7. Bergmann, S.R., Senneff, M.J., and Geltman, E.M.: Blunted response of myocardial perfusion to dipyridamole in older adults. (Letter) *J. Nucl. Med.* 1992; 33:1426-1427.
8. Gropler, R.J. and Bergmann, S.R.*: Myocardial viability. (Letter) *J. Nucl. Med.* 1991; 32:1315-1316.
9. Bergmann, S.R.*, Sobel, B.E., and Eisen, H.J.: Detecting rejection of canine cardiac allograft with indium-111 lymphocytes. (Letter) *J. Nucl. Med.* 1988; 29: 2018-2019.
10. Bergmann, S.R.*: Thrombolysis and angioplasty in acute myocardial infarction. (letter) *N. Engl. J. Med.* 1988; 318:576.
11. Bergmann, S.R.*, Collen, D., Sobel, B.E.: Coronary thrombolysis with tissue-type plasminogen activator. (Correspondence) *N. Engl. J. Med.* 1984; 310:1534-1535.

Abstracts

(>255. Truncated for brevity. Available on request). Only shown for last 3 years.

1. Bajpayee G, Hanan J, Gingrut S, Misra D, Shinnar M, **Bergmann SR**. Left Ventricular Ejection Fraction: Differences Based on Imaging Modality. *J. Nucl. Cardiol.* 21:784-785, 2014.
2. Bajpayee G, Duanmu Y, Lucido D, Filopei J, Kong C, Yuzuk N, Quintero L, Preeshagul I, Husk G, **Bergmann SR**. Who Should Get a CT for Pulmonary Embolism in the Emergency Department? An Analysis of Four Different Clinical Scoring Systems. American Thoracic Society, Denver, CO. May, 2015.
3. Bajpayee G, Misra D, Lucido D, Kabra N, **Bergmann SR**. Gender Based Normal Limits for Left Ventricular EF and Volumes Across Imaging Modalities. *J. Nucl. Cardiol.* 22:757, 2015.

PRESENTATIONS:

Major Invited Lectures

1. Acute Coronary Syndromes – Internal Medicine Society of the Republic of Moldova, Chisinau, Moldova, 2011.

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

2. Weiden-Perlman Lecture: The Changing Paradigm of Chest Pain Evaluation. New York Cardiological Society, New York, NY, 2006.
3. American Society of Nuclear Cardiology Board Review Course; Chicago and Montreal, 2006.
4. American Society of Nuclear Cardiology Board Review Course; Chicago, IL and Seattle, WA, 2005.
5. "Read with the Experts: Myocardial Viability Imaging." Case Presenter - American College of Cardiology, 2005, 54th Annual Scientific Session, Orlando, FL.
6. Positron Emission Tomography Imaging. American College of Cardiology 2005, 54th Annual Scientific Session, Orlando, FL.
7. Myocardial Viability. Radiological Society of North America, Chicago, IL, 2004.
8. Imaging Ischemic Memory with BMIPP. American College of Cardiology, New Orleans, LA, 2004.
9. Novel tracers for cardiac PET. American Society of Nuclear Cardiology. New York, NY, 2004.
10. PET myocardial perfusion and function. American Society of Nuclear Cardiology. New York, NY, 2004.
11. Myocardial Viability. Radiological Society of North America, Chicago, IL, 2003.
12. Novel Tracers for Cardiac PET. American Society of Nuclear Cardiology. Indianapolis, IN, 2003.
13. Fatty Acid Imaging: Ischemic Memory (Advances in Nuclear Cardiology: Beyond Perfusion and Function Imaging Symposium). American College of Cardiology 52nd Annual Scientific Sessions. Chicago, IL, 2003.
14. Cardiac PET (Plenary Session on PET Imaging). Radiological Society of North America, Chicago, IL, 2002.
15. Perfusion imaging with PET agents. 7th Annual American Society of Nuclear Cardiology Symposium and Scientific Session, Baltimore, MD, 2002.
16. Myocardial viability assessment with SPECT and PET. 7th Annual American Society of Nuclear Cardiology Symposium and Scientific Session, Baltimore, MD, 2002.
17. Cardiovascular Imaging: "Congestive Failure: Using PET to Aid Management Decisions" Presented at "The Revolutionary Influence of Imaging in Medicine: New Paradigms for a New Century", New York Cardiological Society, New York, NY, 2001.
18. Evaluating Myocardial Perfusion. State of the Art in Cardiac PET. Society of Nuclear Medicine Annual Meeting, Continuing Education Session. Toronto, Ontario, Canada, 2001.
19. Current Status of Positron Emission Tomography. Meet with the Experts. American College of Cardiology. Anaheim, CA. 2000.
20. PET Imaging: How It Works and When Is It Indicated? New Developments in Nuclear Cardiology. American Society of Nuclear Cardiology 4th Annual Tutorial in Nuclear Cardiology, Washington, D.C., 1999.
21. Functional consequences of gene expression in health and disease. United States Department of Energy, Office of Energy Research, Office of Biological and Environmental Research, Medical Applications and Biophysical Research Division, San Antonio, TX, 1997.
22. Protection of ischemic myocardium by modification of metabolism. International Society for Heart

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Research, Vancouver, British Columbia, Canada, 1997.

23. Is blood flow quantitation possible with SPECT?: Lessons from PET. Society of Nuclear Medicine Annual Meeting, Categorical Seminar. Denver, CO, 1996.
24. Clinical application of myocardial blood flow quantitation with O-15 water. Society of Nuclear Medicine 42nd Annual Meeting, Categorical Seminar "Quantitation of Myocardial Perfusion by PET and MRI," Minneapolis, MN, 1995.
25. Use of positron emission tomography for studies of the heart. Categorical Seminar, Cardiovascular Council, Society of Nuclear Medicine Annual Meeting, Toronto, Canada, 1993.
26. Clinical applications of flow estimates. Society of Nuclear Medicine Annual Meeting. Cincinnati, OH, 1991.
27. Metabolic re-oxygenation and patterns of substrate utilization as measured by positron-emitting fatty acids and acetate. Scientific Conference on Experimental and Clinical Coronary Pathophysiology. American Heart Association. Councils on Arteriosclerosis, Circulation, Clinical Cardiology, and Thrombosis. Durango, CO, 1990.
28. Measurement of myocardial blood flow with positron emission tomography. American Physiological Society/American Thoracic Society joint Fall meeting, Rochester, MN, 1989.
29. The choice of tracers for PET studies of the heart. Continuing Medical Education course. Society of Nuclear Medicine Annual Meeting, St. Louis, MO, 1989.
30. Potentials for the future of cardiac PET. Categorical Seminar, Cardiovascular Council, Society of Nuclear Medicine Annual Meeting, St. Louis, MO, 1989.
31. Noninvasive measurement of myocardial substrate utilization with positron emission tomography. Second International Symposium on Lipid Metabolism in the Normoxic and Ischemic Heart. Maastricht, The Netherlands, 1988.
32. Non-invasive assessment of interventions designed to salvage ischemic myocardium during evolving myocardial infarction. Fifth International Workshop on Regional Myocardial Blood Flow and Ischemic Heart Disease. Celle, West Germany, 1986.
33. Cardiovascular Conference: "Tomography in Nuclear Cardiology" 56th Annual Scientific Sessions, American Heart Association. Anaheim, CA, 1983.
34. Efficacy of intravenously administered plasminogen activator in coronary thrombosis assessed with positron tomography. Fourth International Workshop on Regional Myocardial Blood Flow. Celle, West Germany, 1983.
35. Assessment of regional myocardial plasminogen activator in coronary thrombosis assessed with positron tomography. Fourth International Workshop on Regional Myocardial Blood Flow. Celle, West Germany, 1983.
36. Detection of coronary thrombus with ^{111}In -platelets using a $^{99\text{m}}\text{Tc}$ -RBC subtraction technique. Third International Workshop on Regional Myocardial Blood Flow. Celle, West Germany, 1981.
37. Limitations of cations as perfusion indicators. Third International Workshop on Regional Myocardial Blood Flow. Celle, West Germany, 1981.
38. Approach to assessment of the efficacy of thrombolytic therapy with ^{11}C - palmitate. Third International Workshop on Regional Myocardial Blood Flow. Celle, West Germany, 1981.
39. Exponential infusion of tracers for assessment of myocardial blood flow. Second International Workshop on Regional Myocardial Blood Flow. Celle, West Germany, 1979.
40. The use of $^{13}\text{NH}_3$ as a perfusion indicator. Second International Workshop on Regional Myocardial Blood Flow. Celle, West Germany, 1979.

***Denotes senior or corresponding author**

CURRICULUM VITAE

Steven R. Bergmann, M.D., Ph.D.

Extracurricular Activities

USCG 100 Ton Licensed Master with Towing and Sailing Endorsements

United States Coast Guard Auxiliary – Operational Auxiliarist (AUXOP)

Overseas Medical Missions

Updated 5/13/2025 5:49 PM